{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124436","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.219968+00:00","generated_at":"2026-05-30T02:01:43.838661+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spruce Biosciences reports Q3 2024 net loss of $8.7M; cash runway through end of 2025; topline data expected Dec 2024","bullets":["Net loss of $8.7M in Q3 2024 ($29.5M nine months); cash and equivalents $60.1M as of Sept 30, 2024.","R&D expenses fell to $6.6M (Q3 2024) from $13.5M (Q3 2023) due to study terminations and completions.","Collaboration revenue of $0.6M in Q3 2024 vs $3.1M a year ago, from Kaken Pharmaceutical partnership.","Topline results from CAHmelia-204 (adult CAH) and CAHptain-205 (adult & pediatric CAH) trials expected December 2024.","End-of-Phase 2 meeting with FDA for tildacerfont anticipated in first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124436","json":"https://secwatch.observer/filing/0000950170-24-124436.json","markdown":"https://secwatch.observer/filing/0000950170-24-124436.md","text":"https://secwatch.observer/filing/0000950170-24-124436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/0000950170-24-124436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017024124436/sprb-20241111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:01:43.838661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}